Antioxidant effect of cannabidiol in mice with liver fibrosis
-
摘要:
目的 探讨大麻二酚(CBD)对四氯化碳(CCL4)构建小鼠肝纤维化模型的抗氧化作用。 方法 C57BL/6J雄性小鼠随机分为5组,每组8只,依次为对照组,模型组,低、高剂量CBD组(4、8 mg/kg),秋水仙素组(0.2 mg/kg)。对照组小鼠腹腔注射花生油,剩余小鼠按照5 mL/kg注射30 % CCL4,每周2次,连续10周。CBD组和秋水仙素组在造模的同时每次注射相应剂量药物,对照组和模型组注射生理盐水。自动生化分析仪检测血清丙氨酸氨基转移酶(ALT);天狼星红染色检查肝组织胶原沉积情况;试剂盒检测肝组织氧化应激相关成分超氧化物歧化酶(SOD)、还原型谷胱甘肽(GSH)、丙二醛(MDA);蛋白印迹(WB)检测肝组织还原型烟酰胺腺嘌呤二核苷酸磷酸(NADPH)氧化酶亚基gp91phox、核转录相关因子(Nrf2)表达情况。 结果 与模型组比较,低、高剂量CBD组和秋水仙素组肝指数[分别为(4.71 ± 0.34)%、(4.68 ± 0.20)%、(4.24 ± 0.40)%]、血清ALT含量[分别为(79.38 ± 14.79)、(87.13 ± 9.40)、(77.88 ± 3.76)U/L]明显降低(P < 0.05),胶原沉积显著减少(P < 0.05),肝组织SOD活力[分别为(259.90 ± 36.05)、(223.13 ± 37.49)、(246.39 ± 53.49)U/mgprot]、GSH含量[分别为(63.07 ± 16.71)、(100.38 ± 22.44)、(96.39 ± 19.40)nmol/mgprot]明显增高(P < 0.05),而MDA含量[分别为(2.48 ± 0.43)、(2.74 ± 0.88)、(2.84 ± 0.87)nmol/mgprot]显著降低(P < 0.05),gp91蛋白表达降低(P < 0.05),Nrf2蛋白表达增加(P < 0.05)。 结论 CBD对CCL4诱导的小鼠肝纤维化有一定的保护作用,其作用机制可能与调节gp91、Nrf2蛋白表达,减少自由基、抑制脂质过氧化相关。 Abstract:Objective To explore antioxidant effect of cannabidiol (CBD) in mice with carbon tetrachloride (CCl4)-induced liver fibrosis. Methods Forty male C57BL/6J mice were divided into five groups: a control and a model group, two CBD groups (4 mg/kg and 8 mg/kg) and a colchicine (0.2 mg/kg) group. Intraperitoneal administration of carbon tetrachloride (CCl4) at the dosage of 5 mL/kg body weight was performed for all the mice twice a week for consecutive ten weeks except for those of the control group with intraperitoneal injection of peanut oil; meanwhile, the mice of CBD and colchicine groups were intraperitoneally injected with corresponding dose of medication each time and the control mice with saline. Serum alanine aminotransferase (ALT) was measured with an automatic biochemical analytic instrument; collagen deposition of liver tissue was examined with sirius red staining; superoxide dismutase (SOD), reduced glutathione (GSH) and malondialdehyde (MDA) were measured using commercial kits; gp91/Nrf2 in liver specimens was assessed with Western blot. Results In the mice of treated with low/high CBD and colchicine, significantly lower liver index (4.71 ± 0.34%/4.68 ± 0.20% and 4.24 ± 0.40%), serum ALT (79.38 ± 14.79/87.13 ± 9.40 and 77.88 ± 3.76 U/L), MDA in liver tissues (2.48 ± 0.43/2.74 ± 0.88 and 2.84 ± 0.87 nmol/mgprot) and significantly increased SOD (259.90 ± 36.05/223.13 ± 37.49 and 246.39 ± 53.49 U/mgprot) and GSH (63.07 ± 16.71/100.38 ± 22.44 and 96.39 ± 19.40 nmol/mgprot) in liver tissues were detected compared with those in the model rats (P < 0.05 for all); obviously ameliorated collagen deposition, down-regulated protein expression of gp91 but up-regulated and protein expression of nuclear factor-erythroid 2-related factor-2 (Ntf2) were also observed in liver tissues of the low/high CBD and colchicine groups (all P < 0.05). Conclusion The results suggeste that CBD has protective effect on CCl4-induced liver fibrosis in mice, probably via adjusting protein expression of gp91 and Nrf2, clearing free radicals and inhibiting the occurrence of lipid peroxidation. -
Key words:
- cannabidiol /
- carbon tetrachloride /
- liver fibrosis /
- oxidative stress
-
表 1 CBD对小鼠肝指数、血清ALT及胶原面积影响(
${\bar x}$ ± s,n = 8)组别(mg/kg) 肝指数(%) ALT(U/L) 胶原面积百分比(%) 对照组 4.07 ± 0.31 33.25 ± 2.38 0.29 ± 0.16 模型组 5.82 ± 0.79 a 406.38 ± 98.73 a 3.18 ± 0.93 a CBD 4.0 4.71 ± 0.34 ab 79.38 ± 14.79 b 1.27 ± 0.47 ab 8.0 4.68 ± 0.20 ab 87.13 ± 9.40 b 1.72 ± 0.65 abc 秋水仙素组 4.24 ± 0.40 b 77.88 ± 3.76 b 1.17 ± 0.28 ab 注:与对照组比较,a P < 0.05;与模型组比较,b P < 0.05;与秋水仙素组比较,c P < 0.05。 表 2 CBD对小鼠肝组织 SOD活力、GSH及MDA含量影响(
${\bar x}$ ± s,n = 8)组别(mg/kg) SOD(U/mg prot) GSH(nmol/mg prot) MDA(nmol/mg prot) 对照组 363.98 ± 51.36 99.05 ± 20.89 2.33 ± 0.44 模型组 153.59 ± 25.08 a 30.24 ± 4.34 a 5.87 ± 1.15 a CBD 4.0 259.90 ± 36.05 ab 63.07 ± 16.71 abc 2.48 ± 0.43 b 8.0 223.13 ± 37.49 ab 100.38 ± 22.44 bd 2.74 ± 0.88 b 秋水仙素组 246.39 ± 53.49 ab 96.39 ± 19.40 b 2.84 ± 0.87 b 注:与对照组比较,a P < 0.05;与模型组比较,b P < 0.05;与秋水仙素组比较,c P < 0.05;与低剂量CBD组比较d P < 0.05。 表 3 CBD对小鼠肝组织gp91、Nrf2蛋白表达影响(
${\bar x}$ ± s,n = 8)组别(mg/kg) gp91 Nrf2 对照组 0.25 ± 0.06 1.13 ± 0.02 模型组 1.00 ± 0.03 a 0.71 ± 0.02 a CBD 4.0 0.57 ± 0.03 abc 0.97 ± 0.02 ab 8.0 0.61 ± 0.07 abc 0.94 ± 0.02 ab 秋水仙素组 0.25 ± 0.03 b 1.00 ± 0.03 ab 注:与对照组比较,a P < 0.05;与模型组比较,b P < 0.05;与秋水仙素组比较,c P < 0.05。 -
[1] Guo YJ, Liang XM, Meng MY, et al. Hepatoprotective effects of Yulangsan flavone against carbon tetrachloride (CCl4)-induced hepatic fibrosis in rats[J]. Phytomedicine, 2017, 33: 28 – 35. doi: 10.1016/j.phymed.2017.07.005 [2] Sun HT, Chen GX, Wen B, et al. Oligo-peptide I-C-F-6 inhibits hepatic stellate cell activation and ameliorates CCl4-induced liver fibrosis by suppressing NF-κB signaling and Wnt/β-catenin signaling[J]. Journal of Pharmacological Sciences, 2018, 136(3): 133 – 141. doi: 10.1016/j.jphs.2018.01.003 [3] Aydın MM, Akçalı KC. Liver fibrosis[J]. The Turkish Journal of Gastroenterology, 2018, 29(1): 14 – 21. doi: 10.5152/tjg.2018.17330 [4] Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and anti-inflammatory properties of cannabidiol[J]. Antioxidants (Basel), 2019, 9(1): 21. doi: 10.3390/antiox9010021 [5] De Ternay J, Naassila M, Nourredine M, et al. Therapeutic prospects of cannabidiol for alcohol use disorder and alcohol-related damages on the liver and the brain[J]. Frontiers in Pharmacology, 2019, 10: 627. doi: 10.3389/fphar.2019.00627 [6] Huang W, Zheng Y, Feng H, et al. Total phenolic extract of Euscaphis konishii hayata Pericarp attenuates carbon tetrachloride (CCl4)-induced liver fibrosis in mice[J]. Biomedicine and Pharmacotherapy, 2020, 125: 109932. doi: 10.1016/j.biopha.2020.109932 [7] Rong C, Lee Y, Carmona NE, et al. Cannabidiol in medical marijuana: research vistas and potential opportunities[J]. Pharmacological Research, 2017, 121: 213 – 218. doi: 10.1016/j.phrs.2017.05.005 [8] Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies[J]. Cannabis and Cannabinoid Research, 2017, 2(1): 139 – 154. doi: 10.1089/can.2016.0034 [9] Weiss L, Zeira M, Reich S, et al. Cannabidiol arrests onset of autoimmune diabetes in NOD mice[J]. Neuropharmacology, 2008, 54(1): 244 – 249. doi: 10.1016/j.neuropharm.2007.06.029 [10] 陈瑞, 高晓刚, 张雷, 等. 大麻二酚对大鼠非酒精性脂肪肝的治疗作用及机制[J]. 解放军医学杂志, 2017, 42(6): 515 – 519. doi: 10.11855/j.issn.0577-7402.2017.06.07 [11] Yang LL, Rozenfeld R, Wu DF, et al. Cannabidiol protects liver from binge alcohol-induced steatosis by mechanisms including inhibition of oxidative stress and increase in autophagy[J]. Free Radical Biology and Medicine, 2014, 68: 260 – 267. doi: 10.1016/j.freeradbiomed.2013.12.026 [12] del Zoppo GJ, Frankowski H, Gu YH, et al. Microglial cell activation is a source of metalloproteinase generation during hemorrhagic transformation[J]. Journal of Cerebral Blood Flow and Metabolism, 2012, 32(5): 919 – 932. doi: 10.1038/jcbfm.2012.11 [13] Mukhopadhyay P, Rajesh M, Horváth B, et al. Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflam-matory signaling and response, oxidative/nitrative stress, and cell death[J]. Free Radical Biology and Medicine, 2011, 50(10): 1368 – 1381. doi: 10.1016/j.freeradbiomed.2011.02.021 [14] Han K, Zhang YT, Yang ZW. Cilostazol protects rats against alcohol-induced hepatic fibrosis via suppression of TGF-β1/CTGF activation and the cAMP/Epac1 pathway[J]. Experimental and Therapeutic Medicine, 2019, 17(3): 2381 – 2388. [15] Li X, Xing Y, Mao DC, et al. Codonopis bulleynana forest ex diels (cbFeD) effectively attenuates hepatic fibrosis in CCl4-induced fibrotic mice model[J]. Biomedicine and Pharmacotherapy, 2021, 133: 110960. doi: 10.1016/j.biopha.2020.110960 [16] 赵杰, 齐永芬, 鱼艳荣. 氧化应激在肝纤维化发生发展中的作用[J]. 临床肝胆病杂志, 2019, 35(9): 2067 – 2071. doi: 10.3969/j.issn.1001-5256.2019.09.040 [17] 胡晓霞, 王艳, 王妮. p38MAPK、NF-κB与氧化应激在肝纤维化中作用[J]. 中国公共卫生, 2013, 29(6): 834 – 836. doi: 10.11847/zgggws2013-29-06-17 [18] 史云, 何萍, 孙建超, 等. 大麻素CB2受体激动剂AM1241对肝星状细胞影响[J]. 中国公共卫生, 2016, 32(5): 613 – 617. doi: 10.11847/zgggws2016-32-05-13 [19] Li RD, Zhang P, Li CG, et al. Tert-butylhydroquinone mitigates carbon tetrachloride induced hepatic injury in mice[J]. International Journal of Medical Sciences, 2020, 17(14): 2095 – 2103. doi: 10.7150/ijms.45842 [20] Santos CXC, Tanaka LY, Wosniak J Jr, et al. Mechanisms and implications of reactive oxygen species generation during the unfolded protein response: roles of endoplasmic reticulum oxidoreductases, mitochondrial electron transport, and NADPH oxidase[J]. Antioxidants and Redox Signaling, 2009, 11(10): 2409 – 2427. doi: 10.1089/ars.2009.2625 [21] Guichard C, Moreau R, Pessayre D, et al. NOX family NADPH oxidases in liver and in pancreatic islets: a role in the metabolic syndrome and diabetes?[J]. Biochemical Society Transactions, 2008, 36(5): 920 – 929. doi: 10.1042/BST0360920 [22] Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology[J]. Physiological Reviews, 2007, 87(1): 245 – 313. doi: 10.1152/physrev.00044.2005 [23] 曾超, 陈静, 刘文兵, 等. 电针对脑缺血再灌注小鼠脑组织NOX2/gp91phox表达的影响[J]. 中国中医药科技, 2021, 28(1): 9 – 13. [24] Cuadrado A, Rojo AI, Wells G, et al. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases[J]. Nature Reviews Drug Discovery, 2019, 18(4): 295 – 317. doi: 10.1038/s41573-018-0008-x [25] Yamamoto M, Kensler TW, Motohashi H. The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis[J]. Physiological Reviews, 2018, 98(3): 1169 – 1203. doi: 10.1152/physrev.00023.2017 [26] Zhang CY, Yuan WG, He P, et al. Liver fibrosis and hepatic stellate cells: etiology, pathological hallmarks and therapeutic targets[J]. World Journal of Gastroenterology, 2016, 22(48): 10512 – 10522. doi: 10.3748/wjg.v22.i48.10512 [27] Farr SA, Ripley JL, Sultana R, et al. Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: involvement of transcription factor Nrf2 and implications for Alzheimer disease[J]. Free Radical Biology and Medicine, 2014, 67: 387 – 395. doi: 10.1016/j.freeradbiomed.2013.11.014 [28] Vomund S, Schäfer A, Parnham MJ, et al. Nrf2, the master regulator of anti-oxidative responses[J]. International Journal of Molecular Sciences, 2017, 18(12): 2772. doi: 10.3390/ijms18122772 [29] Wang YP, Mukhopadhyay P, Cao ZX, et al. Cannabidiol attenuates alcohol-induced liver steatosis, metabolic dysregulation, inflam-mation and neutrophil-mediated injury[J]. Scientific Reports, 2017, 7(1): 12064. doi: 10.1038/s41598-017-10924-8